Loading stock data…
NeOnc Technologies Holdings, In (NTHI)
$4.43-0.15 (-3.28%)
After Hours$4.43+0.00 (+0.00%)· Last close Jun 29
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeOnc Technologies Holdings, Inc. in the Healthcare sector is trading at $4.43 with a market capitalization of $113M. Wall Street consensus targets $16.00 (3 analysts), implying a +261.2% move over the next 12 months. The stock is currently near its 52-week low of $3.20, remaining 45.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +261.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $39,990 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.01M↑ | -$13.63M↓ | -$6.93M↓ | -$5.71M↑ | -$31.90M |
| Net Income | -$8.82M↑ | -$15.52M↓ | -$8.62M↓ | -$5.68M↑ | -$32.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$113.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
292.04%
Volume
Today's trading volume
53,439
Recent News
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery. The authorization covers the Company’s NEO100-01, NEO100-02, and NEO100-03 protocols across Phase 1, Phase 1b, and Phase 2 studies in adults, together with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. The breadth of the UAE authorization, spanning three protocols and adult studies from Phase 1 through Phase 2 alongside a defined pediatric pathway, is intended to allow NeOnc to advance multiple stages of clinical development in parallel.
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company’s orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors. The authorization marks the first international regulatory clearance for NEO212 following completion of Phase 1 clinical evaluation and represents a significant step toward expanding the program into multiple global markets. In that study, the Company reported encouraging early signs of clinical activity, including potential durable disease stabilization, in heavily pretreated patients with recurrent glioblastoma (GBM) and brain metastases.
NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different Strategy
With a stock price of $4.64, NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) is among the 8 Best Up and Coming Penny Stocks to Buy Now. On May 19, Alliance Global initiated coverage of NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) with a Buy rating and a $13 price target. The firm highlighted the company’s focus on developing intranasally delivered small-molecule […]
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss ... Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Insider Buys Additional US$185k In NeOnc Technologies Holdings Stock
Investors who take an interest in NeOnc Technologies Holdings, Inc. ( NASDAQ:NTHI ) should definitely note that the...